Search

• Peritoneal carcinomatosis (PC) of pancreatic origin is associated with poor prognosis and typically managed palliatively. • We present a case of a 67-year-old female with widespread PC from a primary pancreatic tumor. • She was managed surgically with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). • At 48 months post CRS and HIPEC, she remains clinically well with no signs of tumor recurrence. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is a well-established procedure commonly employed in the management of peritoneal carcinomatosis (PC) from tumors of various specific origins. However, it is not traditionally used in the management of PC of pancreatic origin due to various reasons, including the aggressive nature of pancreatic tumors. A 67-year-old female presented with a large amount of intractable malignant ascites. Computed tomography (CT) imaging showed a nodule in the right paracolic gutter. A diagnostic laparoscopy and omental biopsy showed a well-differentiated adenocarcinoma of pancreatic origin. She was initially not considered suitable for CRS and HIPEC due to apparent liver metastases on CT imaging and was arranged to undergo palliative chemotherapy; however, due to her large amount of refractory ascites and a suspected ruptured right krukenberg tumor, surgical intervention was offered. We performed CRS, bilateral salpingo-oophorectomy, and an omentectomy with a CC (completeness of cytoreduction) score of 1. HIPEC with mitomycin C was also administered. Notably, our patient remains clinically well at 48-months post CRS and HIPEC, with no signs or symptoms suggestive of tumor recurrence. Despite the current lack of evidence supporting the use of CRS and HIPEC in the curation of PC of pancreatic origin, this case report highlights the importance of patient selection in determining suitability for CRS. In the presence of positive prognostic factors and favorable tumor histology, CRS and HIPEC is a potential curative procedure that could be offered to highly selected patients presenting with PC from a primary pancreatic malignancy. [ABSTRACT FROM AUTHOR]

Abstract: Objective: To study the epidemiological features of pancreatic cystadenoma and cystadenocarcinoma in China during the last 10 years and to analyze the diagnosis and treatment. Methods: Reports on pancreatic cystadenoma and cystadenocarcinoma published from 2000 to 2009 were retrieved from various databases, such as WANFANG data, VIP web and China National Knowledge Infrastructure (CNKI). The epidemiological features of pancreatic cystadenoma and cystadenocarcinoma and its diagnosis and treatment were analyzed. Results: Totally 1 865 patients with pancreatic cystadenoma and cystadenocarcinoma were reported in China during the last 10 years. The male to female ratio was approximately 1:2.1. The accurate ages were reported in 1 536 cases, the average age of them was 50.8 years, whose average age from 40 to 60 years old accounted 75.9% of the patients. 65.3% of the cases were located in East China and Central China. Abdominal pain was the main clinical manifestation and was found in 54.9% of the patients. Pancreatoduodenectomy and resection of body and tail of the pancreas were the main procedure for the treatment of pancreatic cystadenoma and cystadenocarcinoma. Conclusion: Pancreatic cystadenoma and cystadenocarcinoma were mainly found in older women in East and Central China. Preoperative diagnosis is difficult. Pancreatoduodenectomy and resection of pancreatic body and tail were the main procedure for the treatment of pancreatic cystadenoma and cystadenocarcinoma. [Copyright &y& Elsevier]